The significant increase in profit was driven by improvements in the BioMedical and Healthcare divisions.
ITL BioMedical won new customers, grew its product portfolio and benefited from improved market conditions.
ITL Healthcare achieved improved profitability from strategic sourcing and customer initiatives whilst costs have been carefully controlled.
ITL's investment in MyHealthTest, the direct to consumer pathology test provider for major chronic diseases, has focused on critical systems development and expanding the range of tests.
ITL intends to continue reducing identified key risks, drive product growth and enter new markets in order to keep driving business growth.
The Board expects a strong result for the full financial year even allowing for some seasonality in the 2nd half year.
About ITL Limited
ITL Limited (ASX:ITD) is an innovative global medical technology company that creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the blood culture testing market, estimated to be worth US$3.3bn.
ITL maintains four divisions including ITL BioMedical, ITL Healthcare, ITL Clinical and MyHealthTest. The Company holds an IP portfolio of 48 patents and sells into 55 countries, protecting healthcare workers in millions of procedures annually.
For more information or inquiries please email email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/itl-profit-doubles-in-half-year-20162017-results-300412848.html
SOURCE ITL Limited